VIVIMEDLAB Stock Overview
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vivimed Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹4.95 |
| 52 Week High | ₹13.95 |
| 52 Week Low | ₹4.85 |
| Beta | 0.92 |
| 1 Month Change | 0% |
| 3 Month Change | -1.00% |
| 1 Year Change | -45.90% |
| 3 Year Change | -71.71% |
| 5 Year Change | -87.79% |
| Change since IPO | -88.68% |
Recent News & Updates
Recent updates
Is Vivimed Labs (NSE:VIVIMEDLAB) Weighed On By Its Debt Load?
Mar 30
Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?
Dec 14Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)
Jun 30Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)
Feb 22Did Vivimed Labs Limited (NSE:VIVIMEDLAB) Insiders Buy Up More Shares?
Jan 19Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?
Nov 25
Are Insiders Buying Vivimed Labs Limited (NSE:VIVIMEDLAB) Stock?
Sep 22Is Vivimed Labs (NSE:VIVIMEDLAB) Using Debt In A Risky Way?
Jul 31Shareholder Returns
| VIVIMEDLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0% | -4.0% | -1.8% |
| 1Y | -45.9% | 20.3% | 6.2% |
Return vs Industry: VIVIMEDLAB underperformed the Indian Pharmaceuticals industry which returned 30.3% over the past year.
Return vs Market: VIVIMEDLAB underperformed the Indian Market which returned 19.4% over the past year.
Price Volatility
| VIVIMEDLAB volatility | |
|---|---|
| VIVIMEDLAB Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: VIVIMEDLAB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VIVIMEDLAB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 607 | Santosh Varalwar | www.vivimedlabs.com |
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates in two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments.
Vivimed Labs Limited Fundamentals Summary
| VIVIMEDLAB fundamental statistics | |
|---|---|
| Market cap | ₹410.42m |
| Earnings (TTM) | -₹3.22b |
| Revenue (TTM) | ₹1.73b |
0.2x
P/S Ratio-0.1x
P/E RatioIs VIVIMEDLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIVIMEDLAB income statement (TTM) | |
|---|---|
| Revenue | ₹1.73b |
| Cost of Revenue | ₹2.62b |
| Gross Profit | -₹886.40m |
| Other Expenses | ₹2.33b |
| Earnings | -₹3.22b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -38.82 |
| Gross Margin | -51.14% |
| Net Profit Margin | -185.70% |
| Debt/Equity Ratio | 960.3% |
How did VIVIMEDLAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/28 00:30 |
| End of Day Share Price | 2023/07/31 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vivimed Labs Limited is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rashmi Sancheti Shetty | Anand Rathi Shares and Stock Brokers Limited |
| Anil Burra | FirstCall Research |
| null null | K.R. Choksey Shares & Securities Private Ltd. |